Silence Therapeutics (SLN) Accounts Payables: 2019-2025
Historic Accounts Payables for Silence Therapeutics (SLN) over the last 7 years, with Sep 2025 value amounting to $17.0 million.
- Silence Therapeutics' Accounts Payables rose 191.64% to $17.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.0 million, marking a year-over-year increase of 191.64%. This contributed to the annual value of $16.4 million for FY2024, which is 5.55% up from last year.
- According to the latest figures from Q3 2025, Silence Therapeutics' Accounts Payables is $17.0 million, which was up 18.74% from $14.3 million recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' Accounts Payables registered a high of $18.8 million during Q1 2025, and its lowest value of -$18.9 million during Q2 2024.
- In the last 3 years, Silence Therapeutics' Accounts Payables had a median value of -$13.3 million in 2024 and averaged -$1.4 million.
- In the last 5 years, Silence Therapeutics' Accounts Payables tumbled by 287.19% in 2023 and then soared by 241.41% in 2025.
- Silence Therapeutics' Accounts Payables (MRQ) stood at $14.5 million in 2021, then increased by 1.94% to $14.8 million in 2022, then increased by 4.86% to $15.5 million in 2023, then increased by 5.55% to $16.4 million in 2024, then grew by 3.62% to $17.0 million in 2025.
- Its Accounts Payables was $17.0 million in Q3 2025, compared to $14.3 million in Q2 2025 and $18.8 million in Q1 2025.